KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Short-term Investments (2016 - 2025)

Historic Short-term Investments for Rigel Pharmaceuticals (RIGL) over the last 17 years, with Q3 2025 value amounting to $88.6 million.

  • Rigel Pharmaceuticals' Short-term Investments rose 84044.79% to $88.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $88.6 million, marking a year-over-year increase of 84044.79%. This contributed to the annual value of $20.6 million for FY2024, which is 1479.27% down from last year.
  • According to the latest figures from Q3 2025, Rigel Pharmaceuticals' Short-term Investments is $88.6 million, which was up 84044.79% from $55.0 million recorded in Q2 2025.
  • Over the past 5 years, Rigel Pharmaceuticals' Short-term Investments peaked at $112.7 million during Q3 2021, and registered a low of $9.4 million during Q3 2024.
  • For the 5-year period, Rigel Pharmaceuticals' Short-term Investments averaged around $44.9 million, with its median value being $31.4 million (2025).
  • Per our database at Business Quant, Rigel Pharmaceuticals' Short-term Investments plummeted by 7781.63% in 2023 and then surged by 84044.79% in 2025.
  • Quarter analysis of 5 years shows Rigel Pharmaceuticals' Short-term Investments stood at $106.1 million in 2021, then tumbled by 68.19% to $33.7 million in 2022, then dropped by 28.45% to $24.1 million in 2023, then fell by 14.79% to $20.6 million in 2024, then skyrocketed by 330.66% to $88.6 million in 2025.
  • Its last three reported values are $88.6 million in Q3 2025, $55.0 million for Q2 2025, and $31.4 million during Q1 2025.